Inside Precision Medicine July 23, 2024
Cardurion Pharmaceuticals has raised a $260M Series B financing led by Ascenta Capital to support development of a first-in-class phosphodiesterase-9 (PDE9) inhibitor for heart failure and a Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor with “broad therapeutic potential,” according to the company. Both drug candidates are in Phase II trials. The cardiovascular drug market is one of the world’s largest.
The biotech is working on signaling pathways that regulate heart cell function with the goal of reversing pathophysiological mechanisms that drive cardiovascular disease.The company’s two lead drug candidates are PDE9 inhibitor CRD‑750 and CaMKII inhibitor CRD-4730. The funds will also be used to expand the cardiovascular indications for Cardurion’s portfolio of drug candidates and acquire new drug candidates.
PDE9 is elevated...
Today's Sponsors
Today's Sponsor